<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025605</url>
  </required_header>
  <id_info>
    <org_study_id>BXCL501-105</org_study_id>
    <nct_id>NCT05025605</nct_id>
  </id_info>
  <brief_title>Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioXcel Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cognitive Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioXcel Therapeutics Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute&#xD;
      agitation and either bipolar disorder or schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll approximately 120 subjects randomized to dose regimens of 80 µg or 120&#xD;
      µg BCXL501 or placebo. Subjects with acute agitation will include male and female children&#xD;
      and adolescents who are either newly admitted to a hospital setting or already admitted and&#xD;
      experiencing acute agitation. Subjects will be domiciled in a clinical research setting or&#xD;
      hospitalized to remain under medical supervision while undergoing screening procedures to&#xD;
      assess eligibility. Efficacy and safety assessments will be conducted periodically before and&#xD;
      after dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">June 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study will randomize subjects 1:1:1 to receive BXCL501 80 μg, BXCL501 120 μg, or matching placebo film,</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Blind, Placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary End Point</measure>
    <time_frame>120 minutes</time_frame>
    <description>Absolute change from baseline in the Positive and Negative Syndrome Scale - Excited Component (PEC) total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key Secondary End Point</measure>
    <time_frame>90, 60, 45, 30, 20,10 minutes</time_frame>
    <description>Absolute change from baseline in the PEC total score</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizo-Affective Disorder</condition>
  <condition>Schizophreniform; Schizophrenic</condition>
  <condition>Bipolar Disorder I</condition>
  <condition>Bipolar Disorder II</condition>
  <arm_group>
    <arm_group_label>80 Micrograms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual film containing 80 micrograms Dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 Micrograms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual film containing 120 micrograms Dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sublingual Placebo film</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BXCL501</intervention_name>
    <description>Sublingual film containing 80 Micrograms BXCL501</description>
    <arm_group_label>80 Micrograms</arm_group_label>
    <other_name>Dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Film</intervention_name>
    <description>Matching Sublingual Placebo film</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BXCL501</intervention_name>
    <description>Sublingual film containing 120 Micrograms BXCL501</description>
    <arm_group_label>120 Micrograms</arm_group_label>
    <other_name>Dexmedetomidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects between the ages of 10-17 years, inclusive, with bipolar&#xD;
             disorder (DSM-5 criteria) and 13-17 years, inclusive, in subjects with schizophrenia&#xD;
             (DSM-5 criteria).&#xD;
&#xD;
          2. Patients who are judged to be clinically agitated at Screening and Baseline with a&#xD;
             total score of ≥14 on the 5 items comprising the PANSS Excited Component (PEC).&#xD;
&#xD;
          3. Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC at Baseline.&#xD;
&#xD;
          4. Participants who agree to use a medically acceptable and effective birth control&#xD;
             method&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with agitation caused by acute intoxication, including alcohol or drugs of&#xD;
             abuse (with the exception of THC) during urine screening.&#xD;
&#xD;
          2. Use of benzodiazepines or other hypnotics or oral or short-acting intramuscular&#xD;
             antipsychotic drugs in the 4 hours before study treatment.&#xD;
&#xD;
          3. Patients who are judged to be at significant risk of suicide.&#xD;
&#xD;
          4. Patients with serious or unstable medical illnesses.&#xD;
&#xD;
          5. Patients who have received an investigational drug within 30 days prior to the current&#xD;
             agitation episode.&#xD;
&#xD;
          6. Patients who are considered by the investigator, for any reason, to be an unsuitable&#xD;
             candidate for receiving the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa Hemsen</last_name>
    <phone>475-25-5899</phone>
    <email>Lhemsen@bioxceltherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cedric Burg</last_name>
    <email>CBurg@bixceltherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>475-254-5899</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bioxcel CTM</last_name>
      <phone>475-254-5899</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

